]>
IRCT20210526051407N3 IRCT 2026-10-30 Iran University of Medical Sciences Clinical trial study of bone repair product NMImETIC Peptide Nanofibers in Patients with Leg Length Discrepancy Clinical trial study of bone repair product NMImETIC Peptide Nanofibers in Patients with Leg Length Discrepancy 2027-09-29 anticipated 6 Pending https://irct.ir/trial/93590 interventional Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 1 Compromised bone regeneration. Intervention group: Single-dose percutaneous injection of NMImETIC Peptide Nanofibers bone-graft product (Tavakol BioMimetic Technologies Co) at the fracture site. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is Patient should give us a permission
public Shima Tavakol
Iran University of Medical Sciences, Next to Milad Tower, Tehran, Iran
Tehran Iran (Islamic Republic of) 1449614535 +98 913 361 4037 nanomimetic@gmail.com Iran University of Medical Sciences scientific Shima Tavakol
Iran University of Medical Sciences, Next to Milad Tower, Tehran, Iran
Tehran Iran (Islamic Republic of) 1449614535 +98 913 361 4037 nanomimetic@gmail.com Iran University of Medical Sciences Iran (Islamic Republic of) Iran (Islamic Republic of) age 18-70 year-old Men and women Patients who underwent MTN surgery and exhibited inadequate bone healing after a 4-month follow-up period Willingness to participate in all phases of the study Patient with Leg Length Discrepancy 18 years 70 years Both Alcohol consumption Pregnancy or lactation Uncontrolled diabetes mellitus Autoimmune or immunodeficiency disorders Medical conditions that could interfere with study outcomes (e.g., neurological, psychiatric, or infectious diseases). Current use of oral bisphosphonates or a history of intravenous bisphosphonate therapy Malignancy (cancer) or current chemotherapy treatment. Conditions related to calcium malabsorption Tobacco use M84.36 Stress fracture, tibia and fibula Treatment - Drugs Intervention group: Single-dose percutaneous injection of NMImETIC Peptide Nanofibers bone-graft product (Tavakol BioMimetic Technologies Co) at the fracture site Bone regeneration. Timepoint: Before intervention and 4 months after intervention. Method of measurement: X-Ray. Pain and Infection. Timepoint: Before intervention and 2 weeks after intervention. Method of measurement: VAS and observationa. Tavakol BioMimetic Technologies Iran University of Medical Sciences Tavakol BioMimetic Technologies Approved 2026-09-13 Iran University of Medical Sciences Iran University of Medical Sciences, next to Milad tower, Hemmat Highway, Tehran Tehran Tehran Iran (Islamic Republic of)